P-96 Quality of life in late-stage cancer patients on immune checkpoint inhibitor therapy

Abstract

Immune checkpoint inhibitors are a successful therapy for cancer patients and patient related outcomes compared with cytotoxics. Unfortunately Immune checkpoint inhibitors (ICI) can have unpredictable toxicities that have a severe impact on Health-related Quality of life and may lead to treatment withdrawal. This study attempts to further characterise patient’s quality of life on these treatments and identify any trends in any patient groups.